Wojciech Golusiñski

Prof. Wojciech Golusiñski


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2021 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
MRMagdalena Richter
Magdalena Richter
OPOliwia Piwocka
Oliwia Piwocka
MMMarika Musielak
Marika Musielak
IPIgor Piotrowski
Igor Piotrowski
WSWiktoria Suchorska
Wiktoria Suchorska
TTTomasz Trzeciak
Tomasz Trzeciak
Primary cancer cell lines are ex vivo cell cultures originating from resected tissues during biopsies and surgeries. Primary cell cultures are objects of intense research due to their high impact on molecular biology and oncology advancement. Initially, the patient-derived specimen must be subjected to dissociation and isolation. Techniques for tumour dissociation are usually reliant on the organisation of connecting tissue. The most common methods include enzymatic digestion (with collagenase, dispase, and DNase), chemical treatment (with ethylene diamine tetraacetic acid and ethylene glycol tetraacetic acid), or mechanical disaggregation to obtain a uniform cell population. Cells isolated from the tissue specimen are cultured as a monolayer or three-dimensional culture, in the form of multicellular spheroids, scaffold-based cultures (i.e., organoids), or matrix-embedded cultures. Every primary cell line must be characterised to identify its origin, purity, and significant features. The process of characterisation should include different assays utilising specific (extra- and intracellular) markers. The most frequently used approaches comprise immunohistochemistry, immunocytochemistry, western blot, flow cytometry, real-time polymerase chain reaction, karyotyping, confocal microscopy, and next-generation sequencing. The growing body of evidence indicates the validity of the usage of primary cancer cell lines in the formulation of novel anti-cancer treatments and their contribution to drug development.

15 March 2009 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
MNMuhammad Zaeem Noman
Muhammad Zaeem Noman
SBStéphanie Buart
Stéphanie Buart
JPJos Van Pelt
Jos Van Pelt
CRCatherine Richon
Catherine Richon
MHMeriem Hasmim
Meriem Hasmim
SCSalem Chouaib
Salem Chouaib
Hypoxia is an essential component of tumor microenvironment. In this study, we investigated the influence of hypoxia (1% PO2) on CTL-mediated tumor cell lysis. We demonstrate that exposure of target tumor cells to hypoxia has an inhibitory effect on the CTL clone (Heu171)-induced autologous target cell lysis. Such inhibition correlates with hypoxia-inducible factor-1α (HIF-1α) induction but is not associated with an alteration of CTL reactivity as revealed by granzyme B polarization or morphological change. Western blot analysis indicates that although hypoxia had no effect on p53 accumulation, it induced the phosphorylation of STAT3 in tumor cells by a mechanism at least in part involving vascular endothelial growth factor secretion. We additionally show that a simultaneous nuclear translocation of HIF-1α and phospho-STAT3 was observed. Interestingly, gene silencing of STAT3 by small interfering RNA resulted in HIF-1α inhibition and a significant restoration of target cell susceptibility to CTL-induced killing under hypoxic conditions by a mechanism involving at least in part down-regulation of AKT phosphorylation. Moreover, knockdown of HIF-1α resulted in the restoration of target cell lysis under hypoxic conditions. This was further supported by DNA microarray analysis where STAT3 inhibition resulted in a partly reversal of the hypoxia-induced gene expression profile. The present study demonstrates that the concomitant hypoxic induction of phopho-STAT3 and HIF-1α are functionally linked to the alteration of non-small cell lung carcinoma target susceptibility to CTL-mediated killing. Considering the eminent functions of STAT3 and HIF-1α in the tumor microenvironment, their targeting may represent novel strategies for immunotherapeutic intervention.

1 March 2014 in Radiology and Oncology
Verified
Journal Article
Open access
PDF file
EMEwa Majchrzak
Ewa Majchrzak
BSBartosz Szybiak
Bartosz Szybiak
AWAnna Wegner
Anna Wegner
PPPiotr Pienkowski
Piotr Pienkowski
JPJakub Pazdrowski
Jakub Pazdrowski
Wojciech GolusiñskiWojciech Golusiñski
Wojciech Golusiñski
Background. Head and neck squamous cell carcinoma (HNSCC) is a disease of middle-aged to elderly adults. However, an increased incidence of HNSCC in young people under 45 years of age has been reported recently. In the present review, we focused on the epidemiology and aetiology of HNSCC in adults under 45 years of age.Methods. We reviewed literature related to HNSCC in adult patients less than 45 years of age and discussed current treatment options and prognosis.Results. HNSCC in young adults is associated with a higher incidence rate in nonsmokers, lower female-to-male ratio, a higher percentage of oral cavity and oropharynx tumours, and fewer second primary tumours. However, aside from traditional risk factors of tobacco and alcohol exposure, the causes of these cancers in young adults remain unclear. Agents that might contribute to risk include infection with high-risk human papillomavirus subtypes as well as genetic factors or immunodeficiency status. The expected increase in incidence and mortality of the young with HNSCC may become a major public health concern if current trends persist, particularly lifestyle habits that may contribute to this disease.Conclusions. Given the younger age and potential long-term adverse sequelae of traditional HNSCC treatments, young adults should be treated on a case-by-case basis and post-therapy quality of life must be considered in any treatment-decision making process.

22 December 2015 in Oncology Reports
Verified
Journal Article
Closed access
WSWiktoria Suchorska
Wiktoria Suchorska
MLMichał Stefan Lach
Michał Stefan Lach
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

3 August 2022 in Oral Oncology
Verified
Journal Article
Open access
ILIrma M. Verdonck-de Leeuw
Irma M. Verdonck-de Leeuw
CDCamilla Dawson
Camilla Dawson
LLLisa Licitra
Lisa Licitra
JEJesper Grau Eriksen
Jesper Grau Eriksen
SHSefik Hosal
Sefik Hosal
CLChristiaan René Leemans
Christiaan René Leemans
Survivors of head and neck cancer can experience long-term consequences of the cancer and subsequent treatments even after the cancer has resolved. Increasingly clinicians are aware of the social, psychological, financial, and emotional impacts of these cancers, in addition to the support required for the physical symptoms. This review provides recommendations on the long-term management and support required for survivors of head and neck cancer in the European healthcare setting.

25 May 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
BMBerta Victoria Martinez
Berta Victoria Martinez
JDJoseph M. Dhahbi
Joseph M. Dhahbi
YLYury Nunez Lopez
Yury Nunez Lopez
KLKatarzyna Lamperska
Katarzyna Lamperska
PGPaweł Golusiński
Paweł Golusiński
MMMichal M. Masternak
Michal M. Masternak
The Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most common human cancer, causing 350,000 individuals die worldwide each year. The overall prognosis in HNSCC patients has not significantly changed for the last decade. Complete understanding of the molecular mechanisms in HNSCC carcinogenesis could allow an earlier diagnosis and the use of more specific and effective therapies. In the present study we used deep sequencing to characterize small non-coding RNAs (sncRNAs) in serum from HNSCC patients and healthy donors. We identified, for the first time, a multi-marker signature of 3 major classes of circulating sncRNAs in HNSCC, revealing the presence of circulating novel and known miRNAs, and tRNA- and YRNA-derived small RNAs that were significantly deregulated in the sera of HNSCC patients compared to healthy controls. By implementing a triple-filtering approach we identified a subset of highly biologically relevant miRNA-mRNA interactions and we demonstrated that the same genes/pathways affected by somatic mutations in cancer are affected by changes in the abundance of miRNAs. Therefore, one important conclusion from our work is that during cancer development, there seems to be a convergence of oncogenic processes driven by somatic mutations and/or miRNA regulation affecting key cellular pathways.